KR102676274B1 - 세레브로리신의 용도 - Google Patents

세레브로리신의 용도 Download PDF

Info

Publication number
KR102676274B1
KR102676274B1 KR1020207007069A KR20207007069A KR102676274B1 KR 102676274 B1 KR102676274 B1 KR 102676274B1 KR 1020207007069 A KR1020207007069 A KR 1020207007069A KR 20207007069 A KR20207007069 A KR 20207007069A KR 102676274 B1 KR102676274 B1 KR 102676274B1
Authority
KR
South Korea
Prior art keywords
cerebrolysin
composition
cardasil
treated
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007069A
Other languages
English (en)
Korean (ko)
Other versions
KR20200045503A (ko
Inventor
스테판 윈터
허버트 뫼슬러
Original Assignee
에버 뉴로 파르마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에버 뉴로 파르마 게엠베하 filed Critical 에버 뉴로 파르마 게엠베하
Publication of KR20200045503A publication Critical patent/KR20200045503A/ko
Application granted granted Critical
Publication of KR102676274B1 publication Critical patent/KR102676274B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
KR1020207007069A 2017-08-28 2018-08-28 세레브로리신의 용도 Active KR102676274B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188180.8 2017-08-28
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (2)

Publication Number Publication Date
KR20200045503A KR20200045503A (ko) 2020-05-04
KR102676274B1 true KR102676274B1 (ko) 2024-06-18

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007069A Active KR102676274B1 (ko) 2017-08-28 2018-08-28 세레브로리신의 용도

Country Status (15)

Country Link
US (1) US12589118B2 (https=)
EP (2) EP3449931B1 (https=)
JP (1) JP7281450B2 (https=)
KR (1) KR102676274B1 (https=)
CN (1) CN111050780B (https=)
AU (1) AU2018326339A1 (https=)
CA (1) CA3073991A1 (https=)
EA (1) EA202090108A1 (https=)
ES (2) ES2767070T3 (https=)
HR (1) HRP20200031T1 (https=)
MX (1) MX2020002267A (https=)
PH (1) PH12020500376A1 (https=)
PL (2) PL3449931T3 (https=)
UA (1) UA129400C2 (https=)
WO (1) WO2019042983A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198037A1 (en) * 2019-03-25 2020-10-01 The University Of Vermont Methods to promote cerebral blood flow in the brain
WO2022013236A1 (en) 2020-07-13 2022-01-20 Ever Neuro Pharma Gmbh Method for producing a mammalian brain protein hydrolysate
IL307903A (en) * 2021-06-02 2023-12-01 Regeneron Pharma Treatment of cerebrovascular disease with Notts homolog protein factors 3 neurogenic locus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP2334287A4 (en) 2008-08-20 2013-12-25 Univ Texas MELT EXTRUSION OF MULTIPARTICLES WITH MODIFIED RELEASE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC Medicine, 제15권, 논문번호 41 (2017. 2. 24.)
Neurol. Sci., 제34권, 제4호, 제553-556면 (2012. 8. 10.)
Ning Chen 등, "Cerebrolysin for vascular dementia", Cochrane Database Syst. Rev., 제1호, 논문번호 CD008900 (2013. 1. 31.)

Also Published As

Publication number Publication date
PL3449931T3 (pl) 2020-06-01
KR20200045503A (ko) 2020-05-04
CN111050780B (zh) 2023-11-03
PL3675879T3 (pl) 2022-02-14
JP2020531568A (ja) 2020-11-05
UA129400C2 (uk) 2025-04-16
HRP20200031T1 (hr) 2020-03-20
ES2901508T3 (es) 2022-03-22
PH12020500376A1 (en) 2020-12-07
US20200376040A1 (en) 2020-12-03
JP7281450B2 (ja) 2023-05-25
CA3073991A1 (en) 2019-03-07
EP3675879B1 (en) 2021-09-15
AU2018326339A1 (en) 2020-03-05
EP3449931A1 (en) 2019-03-06
ES2767070T3 (es) 2020-06-16
EP3675879A1 (en) 2020-07-08
CN111050780A (zh) 2020-04-21
EA202090108A1 (ru) 2020-03-31
EP3449931B1 (en) 2019-10-16
MX2020002267A (es) 2020-10-22
WO2019042983A1 (en) 2019-03-07
US12589118B2 (en) 2026-03-31

Similar Documents

Publication Publication Date Title
Mann et al. The noradrenergic system in Alzheimer and multi-infarct dementias.
CN102548571B (zh) 用于预防和治疗脑部疾病和疾病状态的组合物和方法
Berk et al. Successes and failures for drugs in late-stage development for Alzheimer’s disease
US9480658B2 (en) Modulation of synaptic maintenance
KR102676274B1 (ko) 세레브로리신의 용도
JP7126940B2 (ja) 補体活性のモジュレーター
Ma et al. Propofol attenuates inflammatory damage via inhibiting NLRP1-Casp1-Casp6 signaling in ischemic brain injury
Jiang et al. Laquinimod exerts anti-inflammatory and antiapoptotic effects in retinal ischemia/reperfusion injury
Broussalis et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies
KR20180004158A (ko) Tpp1 제제 및 cln2 질환의 치료 방법
US20120009125A1 (en) Apoe4 and apoj biomarker-based prevention and treatment of dementia
Zhan et al. Perivascular macrophages in the central nervous system: insights into their roles in health and disease
Zhang et al. Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis
HK40026040B (en) Cerebrolysin for use in the treatment of cadasil
EA040978B1 (ru) Применение церебролизина
Cordano et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
Chen et al. Exploring the protective effects of Qiju Granule in a rat model of dry age-related macular degeneration
Wang et al. Age-and Sex-Specific Regulation of Serine Racemase in the Retina of an Alzheimer's Disease Mouse
Hayes Cellular Mechanisms of IGF-1 Neuroprotection After Ischemic Stroke
Noll Spatiotemporal Neuroprotection and Early Regeneration after Ischemic Stroke with Neuregulin-1 Treatment
Matamoros Felipe et al. Citicoline and Coenzyme Q10: Therapeutic Agents for Glial Activation Reduction in Ocular Hypertension
Ramos Pérez et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
Czapski et al. Genetic inactivation of poly (ADP-ribose) polymerase and endothelial nitric oxide synthase prevents energy failure and oxidative damage in the mouse brain during septic shock
Impairment et al. Diffusion Tensor Mr Imaging for Evaluation of Fronto-Subcortical Neural Pathway Changes in Parkinson's Disease With Dementia
Tanik The interplay between Lewy body-like alpha-synuclein aggregates and protein degradation pathways in a cell-based model of Parkinson's disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200310

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210810

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240410

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240613

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration